Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07672561
PHASE3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis
Sponsor: Zhejiang Wenda Pharma Technology LTD.
View on ClinicalTrials.gov
Summary
The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
375
Start Date
2026-03-18
Completion Date
2027-07-30
Last Updated
2026-06-29
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
Drug:WD-890
WD-890 tablet will be administered orally.
DRUG
Drug: placebo
Placebo tablet will be administered orally.
Locations (1)
Hospital of Dermatology, Chinese Academy of Medical Sciences
Nanjing, Jiangsu, China